Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis.

Clin Genet

Institut de Bioquímica Clínica, Servei de Bioquimica i Genètica Molecular, Hospital Clínic, Barcelona, Spain.

Published: August 2007

The term 'pseudodeficiency' is used in lysosomal storage diseases to denote the situation in which individuals show greatly reduced enzyme activity but remain clinically healthy. Pseudodeficiencies have been reported for several lysosomal hydrolases. GM1 gangliosidosis is a rare autosomal recessive lysosomal storage disorder caused by beta-galactosidase hydrolase deficiency as a result of mutations in the GLB1 gene. Until now, two variants altering the beta-galactosidase activity have been described, p.Arg521Cys and p.Ser532Gly. Here we report the new variant p.Arg595Trp in the GLB1 gene, which markedly reduces beta-galactosidase activity when expressed in COS-1 cells. The variant was identified in the healthy father of a girl with GM1 gangliosidosis. He was a heterozygous compound with p.Arg595Trp in trans with one of the disease-causing mutations identified in his daughter; in leukocytes and plasma he showed lower beta-galactosidase activity than that observed in GM1 gangliosidosis carriers. As this family originated from the Basque Country in the north of Spain, we decided to analyse individuals of Basque and non-Basque origin, finding the p.Arg595Trp allele in 3.2% of Basque and in 0.8% of non-Basque alleles. The detection of the presence of alterations resulting in pseudodeficient activity in leukocytes and plasma is important for the correct diagnosis of GM1 gangliosidosis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1399-0004.2007.00843.xDOI Listing

Publication Analysis

Top Keywords

gm1 gangliosidosis
20
glb1 gene
12
beta-galactosidase activity
12
lysosomal storage
8
leukocytes plasma
8
gm1
5
gangliosidosis
5
activity
5
identification novel
4
novel pseudodeficiency
4

Similar Publications

A natural history study of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, or gaucher disease type 2 (RETRIEVE).

Orphanet J Rare Dis

December 2024

Division of Metabolism and Children's Research Center, Reference Center for Inborn Errors of Metabolism, University Children's Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Article Synopsis
  • RETRIEVE is a natural history study focused on the survival and disease progression of early-onset GM1, GM2, and type 2 Gaucher disease (GD2).
  • The study gathered data from 185 patients retrospectively and 40 patients prospectively, revealing varying median survival rates: GM1 (19 months), GM2 (44 months), and GD2 (14 months).
  • The findings noted that hypotonia was widespread among GM1 patients (94.4%), with additional symptoms like strabismus and splenomegaly specifically observed in GD2 patients, confirming known patterns of these rare lysosomal storage disorders.
View Article and Find Full Text PDF

Differential Tractography: A Biomarker for Neuronal Function in Neurodegenerative Disease.

medRxiv

August 2024

Office of the Clinical Director and Medical Genetics Branch, National Human Genome Research Institute, 10 Center Drive, Bethesda MD USA.

GM1 gangliosidosis is an ultra-rare inherited neurodegenerative lysosomal storage disorder caused by biallelic mutations in the gene. GM1 is uniformly fatal and has no approved therapies, although clinical trials investigating gene therapy as a potential treatment for this condition are underway. Novel outcome measures or biomarkers demonstrating the longitudinal effects of GM1 and potential recovery due to therapeutic intervention are urgently needed to establish efficacy of potential therapeutics.

View Article and Find Full Text PDF
Article Synopsis
  • GM1-gangliosidosis (GM1) causes significant brain degeneration, making it difficult to use automated MRI techniques for brain volume analysis. An effective standardized segmentation protocol was created to analyze MRIs from patients with type II GM1.
  • A study involving 25 MRIs from 22 patients assessed the reliability of this segmentation method, focusing on various brain structures and evaluating the consistency between different raters.
  • Results showed that the technique had good inter- and intra-rater reliability, especially for juvenile patients, which can enhance future research and understanding of the disease's progression over time.
View Article and Find Full Text PDF

Generation of an infantile GM1 gangliosidosis induced pluripotent stem cell line (CHOCi005-A) for disease modeling and therapeutic testing.

Stem Cell Res

December 2024

Division of Metabolic Disorders, Children's Hospital of Orange County Specialists, Orange, CA 92868, United States; Department of Pediatrics, University of California-Irvine School of Medicine, Irvine, CA 92697, United States. Electronic address:

Article Synopsis
  • - GM1 gangliosidosis is a rare genetic disorder caused by a deficiency of the enzyme beta-galactosidase, leading to harmful buildup of GM1 ganglioside in the body.
  • - There are limited resources for studying GM1, and obtaining human cell lines for research is challenging, but generating induced pluripotent stem cells (iPSCs) from skin cells of GM1 patients can help with modeling the disease.
  • - The newly developed iPSC lines will be important for testing potential therapies and advancing research in gene therapy for GM1 gangliosidosis.
View Article and Find Full Text PDF

Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells.

Mol Genet Metab

October 2024

Division of Metabolic Disorders, Children's Hospital of Orange County Specialists, Orange, CA 92868, United States; Department of Pediatrics, University of California-Irvine School of Medicine, Irvine, CA 92697, United States. Electronic address:

GM1 gangliosidosis is an autosomal recessive neurodegenerative lysosomal storage disease caused by pathogenic variants in the GLB1 gene, limiting the production of active lysosomal β-galactosidase. Phenotypic heterogeneity is due in part to variant type, location within GLB1, and the amount of residual enzyme activity; in the most severe form, death occurs in infancy. With no FDA approved therapeutics, development of efficacious strategies for the disease is pivotal.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!